Submission of Letter of Offer for Buyback
As filed · Windlas Biotech Limited has informed the Exchange about submission of Letter of Offer for Buyback
What happened
FactWindlas Biotech Limited has announced a buyback of 470,000 fully paid-up equity shares at a price of INR 1,000 per share. The buyback will be conducted in accordance with SEBI regulations, and the dispatch of the Letter of Offer to eligible shareholders will be completed by April 28, 2026. Further details, including the Letter of Offer and Tender Forms, will be available on the company's website.
Why it matters
CapitSignal interpretationA buyback returns cash by retiring shares, so the benefit to a holder depends on the price paid, how many of their shares are accepted, and what the stub is worth afterwards.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Capex
WithdrawnWe are on track for the commercialization of Plant-6 in H1 FY27, which will further strengthen our manufacturing capacity and enable us to support future growth opportunities.
Our Injectables and Plant-2 Extension facilities continue to drive scalable growth, highlighting the effectiveness of our strategic investments.
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Record date and acceptance ratio
- Promoter participation
- Cash left on the balance sheet afterwards
- We are on track for the commercialization of Plant-6 in H1 FY27, which will further strengthen our manufacturi (management committed by H1 FY27)
Evidence
- Windlas Biotech Limited has informed the Exchange about submission of Letter of Offer for Buyback(opens the original filing in a new tab)
- Earlier statement · Q1 FY27
- Latest statement · Q1 FY27
How CapitSignal classified this
- Reasoning:
- BUYBACK base 70; +5 quantified amount; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 75%